Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 88Cyclophosphamide 81Prednisone 48Doxorubicin 44Lenalidomide 37Vincristine 35polatuzumab vedotin 29Magnetic Resonance Spectroscopy 29Gemcitabine 27Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 17tafasitamab 15obinutuzumab 15ibrutinib 14zanubrutinib 13fludarabine phosphate 13pembrolizumab 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × EPOCH protocol × 1 year × Clear all
NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
132 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡